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Background: Fibrosis, an excessive collagen accumulation, results in scar formation, impairing function of vital
organs and tissues. Fibrosis is a hallmark of muscular dystrophies, including the lethal Duchenne muscular
dystrophy (DMD), which remains incurable. Substitution of muscle by fibrotic tissue also complicates gene/cell
therapies for DMD. Yet, no optimal models to study muscle fibrosis are available. In the widely used mdx mouse
model for DMD, extensive fibrosis develops in the diaphragm only at advanced adulthood, and at about two years
of age in the ‘easy-to-access’ limb muscles, thus precluding fibrosis research and the testing of novel therapies.
Methods: We developed distinct experimental strategies, ranging from chronic exercise to increasing muscle
damage on limb muscles of young mdx mice, by myotoxin injection, surgically induced trauma (laceration or
denervation) or intramuscular delivery of profibrotic growth factors (such as TGFβ). We also extended these
approaches to muscle of normal non-dystrophic mice.
Results: These strategies resulted in advanced and enhanced muscle fibrosis in young mdx mice, which persisted
over time, and correlated with reduced muscle force, thus mimicking the severe DMD phenotype. Furthermore,
increased fibrosis was also obtained by combining these procedures in muscles of normal mice, mirroring aberrant
repair after severe trauma.
Conclusions: We have developed new and improved experimental strategies to accelerate and enhance muscle
fibrosis in vivo. These strategies will allow rapidly assessing fibrosis in the easily accessible limb muscles of young
mdx mice, without necessarily having to use old animals. The extension of these fibrogenic regimes to the muscle
of non-dystrophic wild-type mice will allow fibrosis assessment in a wide array of pre-existing transgenic mouse
lines, which in turn will facilitate understanding the mechanisms of fibrogenesis. These strategies should improve
our ability to combat fibrosis-driven dystrophy progression and aberrant regeneration.Background
In skeletal muscle, accumulation of collagens (fibrosis) in
the extracellular matrix (ECM) is most often associated
with the muscular dystrophies, characterized by muscle
wasting, leading to loss of patient mobility. Duchenne
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stated.dystrophies and is caused by loss of the dystrophin protein
due to genetic mutations. As a result, the sarcolemma be-
comes fragile and susceptible to contraction-induced
damage [1]. Skeletal muscle stem cells (satellite cells) me-
diate the repair process, but in the absence of dystrophin,
the muscle undergoes continuous cycles of degeneration
and regeneration, eventually leading to satellite cell deple-
tion and myofiber loss [2-4]. The severity of this childhood-
associated pathology may also be exacerbated by the
growth of myofibers that occurs in boys with DMD over
many years [5]. Affected children eventually succumb to
muscle wasting, with muscle progressively being replacedLtd. This is an Open Access article distributed under the terms of the Creative
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late teens or early twenties from respiratory and cardiac
failure [6]. There are currently only palliative treatments for
DMD patients. Importantly, no effective clinical treatments
are available yet to combat or attenuate fibrosis in patients
with DMD. Halting or diminishing the development of fi-
brosis could not only ameliorate DMD progression, but
could also increase the success of new cell- and gene-based
therapies [7,8]. The mdx mouse strain, the most widely
used animal model for studying human DMD, has a non-
sense mutation in dystrophin exon 23 leading to dystrophin
protein absence [9]. Although mdx mice and DMD patients
share many genetic, biochemical and histological similar-
ities, the clinical manifestations are generally less severe in
mdx mice [10]. While DMD individuals have a high degree
of muscle fibrosis, mdx mice present extensive fibrosis ex-
clusively in the diaphragm muscle. In the limb muscles of
mdx mice, however, fibrosis only becomes apparent around
20 months of age [11]. Therefore, despite our awareness of
the importance of fibrosis in DMD, there is a lack of ap-
propriate mouse models for studying dystrophic skeletal
muscle fibrosis in accessible muscles, such as limb mus-
cles, without requiring nearly two years for fibrosis to ap-
pear. Thus, there is a genuine need to develop mouse
models that present fibrosis at early stages in life and that
more closely mimic human DMD.
In this manuscript, we present several experimental
strategies to simply and effectively advance and enhance
muscle fibrosis in young mdx mice. We use both physio-
logical exercise, as well as more direct tissue-damaging
procedures or delivery of profibrotic growth factors to
limb muscle of young dystrophic mice, and demonstrate
sustained collagen deposition reminiscent of aged mdx
diaphragm muscle, and muscle of human DMD patients.
Notably, we could extend these strategies to induce fi-
brosis in muscles of normal, non-dystrophic mice, which
will facilitate studying fibrosis in a wide array of genetic-
ally modified mouse lines, and this will in turn increase
our understanding of the cells and molecules involved in
fibrosis development. Thus, we offer for the first time, to
the best of our knowledge, a comparative and quantita-
tive set of new and improved strategies for inducing
muscle tissue fibrosis, which will greatly foster our abil-
ity to combat fibrosis-dependent dystrophy progression.
Methods
Mice handling and sample collection
All experiments were approved by the Ethics Committee
of the Pompeu Fabra University (UPF) and performed
according to Spanish and European legislation. Mice were
housed in standard cages under 12-hour light–dark cycles
and fed ad libitum with a standard chow diet. Three-
month-old normal C57Bl/6 J mice (the classic standard la-
boratory mouse strain, hereafter referred to as WT) anddystrophic C57Bl/10scsn-mdx (mdx) male mice were used
in experiments: the background strain for mdx mice is
similar to, but not identical with, the C57Bl/6 J strain. All
operations were performed after injection intraperitoneal
(i.p.) of ketamine/metedomidine anesthesia (50 mg/kg
and 1 mg/kg body weight). Atipamezol (1.0 mg/kg body
weight) by subcutaneous injection was used to reverse
the effects of anesthesia. Mice were sacrificed at the in-
dicated ages and the tissues were immediately processed
to avoid artifacts, either by direct freezing in liquid nitro-
gen for protein and RNA extraction or in 2-methylbutane
cooled with liquid nitrogen for histological analysis, as de-
scribed below.
Skeletal muscle fibrogenic treatments
– Chronic exercise: Mdx mice were exercised three
times per week on a treadmill for 30 minutes at a
speed of 12 meters per minute, with a rest of
5 minutes every 10 minutes of exercise. Mdx mice
of three, four and five months of age were exercised
for three, two and one month, respectively and were
sacrificed at the age of six months, together with
age-matched unexercised control mdx mice. At the
end of the training period muscles were collected
and processed for further analyses.
– Single treatments in WT and mdx mice:
 Myotoxin-induced injuries:
Cardiotoxin injury: Tibialis anterior (TA) muscles
of three-month-old WT or mdx mice were
injected with 50 μl of 10–5 M cardiotoxin (CTX;
Latoxan, Rosans, France). Muscles were collected
at the indicated times on each set of experiments,
which was usually two weeks after myotoxin
injection. Muscle samples were also obtained at
one month post-injection (in WT mice) and two
months post-injection (in mdx mice).
Barium chloride injury: TA muscle of three-
month-old WT mice was injected with 50 μl of
0.2% barium chloride (BaCl2) and was isolated after
two weeks. For repeated BaCl2 injuries, BaCl2 injec-
tions were made in the same muscle, one per week
for six weeks, and muscles were isolated and col-
lected for analysis two weeks after the last injection.
 Traumatic injuries:
Laceration: TA muscles of three-month-old WT
or mdx mice were subjected to laceration (LAC)
as previously described [11,12]. Briefly, the skin
was carefully cut and separated from the
underlying tissue, then the TA muscle of one leg
was cut horizontally at its middle of the length by
making a lesion through 75% of their width and
50% of the muscle thickness with a scalpel.
Contralateral control muscles were sham-operated.
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and one month post-surgery. In mdx mice,
muscles were obtained at two weeks and two
months post-surgery.
Denervation: Muscle denervation (DEN) was
performed as previously described [13,14]. In brief, a
5 mm segment of the sciatic nerve was surgically
removed down to the gluteus maximum from the
right legs. In three-month-old WT mice, TA
muscles were isolated for analysis at two weeks and
one month post-surgery. In three-month-old mdx
mice, TA muscles were collected at two weeks and
two months post-surgery. Contralateral muscles of
sham-operated mice were used as controls on every
single treatment (CTX, BaCl2, LAC and DEN).
 Profibrotic growth factor treatments:
Transforming growth factor beta treatment: 50 ng
of transforming growth factor beta 1 (TGFβ1)
(recombinant human TGFβ1; R&D Systems,
Minneapolis, MN, USA) were injected in the TA
muscle in a volume of 50 μl of phosphate-buffered
saline (PBS, vehicle). Two injections (one per week)
were made in TA muscle of three-month-old mdx
mice, and muscles were collected for analysis two
weeks or two months after the first injection.
Connective tissue growth factor delivery: TA
muscles of three-month-old mdx mice were
injected with 1 × 1011 viral particles of Ad-m
connective tissue growth factor (CTGF) or
Ad-GFP or with PBS (vehicle) [15] as a control in
a total volume of 50 μl. Muscles were collected
two weeks after injury.
– Combined treatments in WT mice:
Cardiotoxin injury combined with denervation: TA
muscles of three-month-old WT mice were injected
with 50 μl of 10–5 M CTX immediately after DEN,
as indicated above. Muscles were collected at two
weeks and one month after the treatments.
Contralateral muscles of non-denervated left legs
were used as controls.
Cardiotoxin injury combined with TGFβ/CTGF
treatment: TA muscles of three-month-old WT mice
were injected with 50 μl of 10–5 M CTX. TGFβ1
was injected intramuscularly twice at day 7 and 10
after cardiotoxin injection. Muscles were collected at
two weeks and one month after the cardiotoxin
injection. Contralateral muscles of sham-operated
legs were used as controls. When indicated, CTGF
adenoviral delivery was performed immediately after
cardiotoxin injection.
Specific information about starting and sampling ages
of mice after the different experimental protocols is in-
cluded in Table S1 in Additional file 1.Dystrophic patients study
Human samples were provided from Dr. J. Colomer
(Hospital Sant Joan de Deu, Barcelona, Spain). DMD diag-
nosis was established on a total absence of dystrophin by
immunohistochemistry and Western blotting. Muscle sam-
ples were obtained by a standard quadriceps muscle biopsy
from six DMD patients (ranging from five to eleven years
of age) and five healthy male human controls of similar age
(seven to fourteen years). Quantification of fibrosis was
carried out by color image segmentation and automatic
measurement using Fiji image analysis software [16]. The
ratio of the total area of fibrosis to the total biopsy area
was used to estimate the extent of fibrosis (fibrosis index).
Histological analysis was performed similarly to mouse
samples, as explained in the next section.
Histological analysis and immunohistochemistry
Cryosections (10 μm thickness) were stained with
hematoxylin/eosin (H&E) or Sirius red (Sigma-Aldrich,
St Louis, MO, USA). Quantification of collagen content
in muscle was performed according to Ardite et al. [11].
Briefly, 10 cryosections were collected in a tube and were
sequentially incubated with a solution containing 0.1%
Fast green in saturated picric acid, washed with distillated
water, incubated with 0.1% Fast green and 0.1% Sirius red
in saturated picric acid, washed with distillated water, and
gently resuspended in a solution of 0.1 M NaOH in abso-
lute methanol (1 vol:1 vol). Absorbance was measured in a
spectrophotometer at 540 and 605 nm wavelengths and
used to calculate total protein and collagen.
Immunohistochemistry on frozen sections was per-
formed using the following primary antibodies: rabbit poly-
clonal collagen I (Coll 1) (Millipore, Billerica, MA, USA),
rabbit polyclonal fibronectin (FN) (Abcam, Cambridge,
MA, USA) and rabbit polyclonal phosphorylated-Smad2/3
(P-Smad2/3) (Abcam). For immunoperoxidase staining,
labeling of sections was performed using the peroxidase
staining kit (Vector Laboratories, Burlingame, CA, USA)
according to the manufacturer’s instructions. For immuno-
fluorescence, secondary antibodies were coupled to Alexa
Fluor 488 or 568 fluorochromes (Invitrogen, Carlsbad,
CA, USA). Stained sections were photographed on a
Leica DM6000B microscope (Leica Microsystems, Wetzler,
Germany).
RNA isolation, reverse transcription (RT) and real-time
quantitative PCR
Total RNA was isolated from muscle tissue using Trizol
(Invitrogen). cDNA was synthesized from 1 μg of total
RNA using the First Strand cDNA Synthesis kit and ran-
dom priming according to the manufacturer’s instructions
(Promega, Madison, WI, USA). RT-PCR was performed
on a LightCycler 480 System using LightCycler 480 SYBR
Green I Master Mix (Roche, Basel, Switzerland) with
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as a housekeeping gene: mL7 5′-GAAGCTCATCTATG
AGAAGGC–3′ and 5′–AAGACGAAGGAGCTGCAGA
AC-3′; mCollagen I, 5′-GGTATGCTTGATCTGTATCT
GC-3′ and 5′-AGTCCAGTTCTTCATTGCATT-3′; mC






3′ and 5′-GAACATCGGTCACTTGCATCT-3′; hTIMP-
1 5′-CTTCTGCAATTCCGACCTCGT-3′ and 5′-CCCT
AAGGCTTGGAACCCTTT-3′; hTGFβ 5′-CCTAA GGC
CAGATCCTGTCCAAGC-3′ and 5′- GTGGGTTTCCA
CCATTAGCAC-3′; hCTGF 5′- CAAGGGCCTCTTCTG
TGACT-3′ and 5′-ACGTGCACTGGTACTTGCAG-3′.Quantification of TGFβ protein
The protein concentration of active and total (active
plus latent) TGFβ1 levels in dystrophic muscle was quan-
tified by ELISA (Promega), following the manufacturer’s
instructions.Muscle force measurement
Muscle strength was determined as described previously
[17]. Briefly, after the indicated days of treatment, mice
were sacrificed and the TA was rapidly excised into a
dish containing oxygenated Krebs-Ringer solution. The
optimum muscle length (Lo) was determined from mi-
cromanipulations of muscle length to produce the max-
imum isometric twitch force. Maximum isometric-specific
tetanic force was determined from the plateau of the
curve of the relationship between specific isometric force
with a stimulation frequency (Hz) ranging from 1 to
200 Hz for 450 ms, with 2 minutes of rest between stimuli.
The force was normalized per total muscle fiber cross-
sectional area (CSA), to calculate the specific net force
(mN/mm2).Statistical analysis
Comparison between groups was done using the non-
parametric Mann–Whitney U test for independent sam-
ples, with a confidence level of 95% being considered
statistically significant. One-way or two-way analysis of
variance (ANOVA) was used for comparisons between
multiple groups as appropriate, and post hoc analysis
was performed using Tukey’s test. All statistical analyses
were performed using GraphPad Prism 5.0 (GraphPad
Software, San Diego, CA, USA). The number of samples
analyzed per group is detailed on each figure. Differences
were considered to be statistically significant at P <0.05.Results
Mdx mice reproduce the human DMD fibrotic phenotype
in aging diaphragm muscle
To recreate as closely as possible the fibrosis status of
human DMD in animal models, we first sought to
characterize in detail distinct fibrosis-associated parame-
ters in muscle biopsies of DMD patients. Compared to
muscles of healthy individuals, we found an increased col-
lagen content in DMD patients, based on Sirius red stain-
ing and collagen quantification, where fibrotic tissue had
replaced the myofiber area (Figure 1A and B). Transform-
ing growth factor-β (TGFβ) has been shown to be a profi-
brotic cytokine in many types of fibrotic tissues and is a
potent stimulator of matrix production, including colla-
gen, by fibroblasts [13,18-22]. We found higher levels of
activated TGFβ protein in muscle biopsies from dys-
trophic children compared to healthy controls (Figure 1C).
Consistent with this, we found enhanced levels of active
Smad2/3 (as indicated by phosphorylated Smad2/3)
(Figure 1D) and TGFβ target genes such as Coll I, FN,
tissue inhibitor of metalloproteinases 1 (TIMP-1) and
CTGF, indicative of functional TGFβ signaling in fi-
brotic DMD muscle (Figure 1E).
The most common experimental model of DMD is the
mdx mouse [23]. We examined the TA limb muscle and
the diaphragm muscle by hematoxylin and eosin (H&E)
and Sirius red staining from young (three months of
age), adult (nine months) and old mdx mice (eighteen to
twenty-four months) in comparison to age-matched WT
muscles. Significant fibrosis, similar to that observed in
human patients, was found in TA muscles of mdx mice
only at old age (>18 months) (Figure 2A, upper panels
and Figure 2D), while adult mdx TA muscles presented
milder fibrosis. In diaphragm muscle, fibrosis increased
age-dependently, reaching near maximum levels in adult
mice of nine months of age and plateauing thereafter
(Figure 2A, lower panels). Furthermore, in TA muscles of
mdx mice, collagen content, activated TGFβ and expres-
sion of ECM-associated molecules started to increase at
adult age but were much higher at old age (Figure 2B, D, F,
G); in the diaphragm muscle, these parameters were mod-
erately increased already at young age (Figure 2C and E,
and Figure S1A and B in Additional file 2). The limited de-
velopment of fibrosis (compared to the diaphragm muscle)
in the easily accessible limb muscles of mdx mice until old
age, reinforces the need for developing new protocols that
will advance muscle fibrosis in young mdx mice.
Exercise training triggers fibrosis in muscles of young
dystrophic mice
In a first attempt to induce and advance muscle fibrosis,
young mdx mice were subjected to a chronic exercise
training routine, known to exacerbate the muscle degen-
eration/regeneration process [24]. Three-month-old mdx
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Figure 1 Quantification of fibrosis in human dystrophic muscle. (A) Representative Sirius red staining of healthy and dystrophic human
muscle sections reveals the extent of collagen deposition in patients with Duchenne muscular dystrophy (DMD). (B) Percentage of fibrosis
(collagen content) in healthy and DMD muscles as measured by Sirius red staining in muscle sections. Data correspond to the mean ± SEM; n = 6
for DMD group and n = 5 for control group. Non-parametric Mann–Whitney U test was used for comparison. **P <0.01 versus healthy controls.
(C) Active transforming growth factor beta 1 (TGFβ1) protein levels measured by ELISA in muscle biopsy material from healthy and DMD muscle.
Data correspond to the mean ± SEM; n = 5 on each group. Non-parametric Mann–Whitney U test; **P <0.01 versus healthy controls. (D) Immuno-
histochemistry for phosphorylated-Smad2/3 (P-Smad2/3) in healthy and dystrophic human muscle sections. (E) Quantitative RT-PCR for collagen I
(Coll 1), fibronectin (FN), tissue inhibitor of metalloproteinases 1(TIMP-1), TGFβ1 and connective tissue growth factor (CTGF) in DMD muscles
compared to healthy muscles (which were given the arbitrary value of 1). Data correspond to the mean ± SEM; n = 4 on each group. Non-parametric
Mann–Whitney U test *P <0.05. Scale bars = 50 μm.
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for up to three months, for 30 minutes each time, at a
speed of 12 meters per minute, with a rest of 5 minutes
every 10 minutes [25]. Muscles of mice exercised for one,
two and three months were compared with age- and sex-
matched unexercised mice. After one month, exercised
mdx mice already showed a worsening of the dystrophic
phenotype (compared to age-matched controls), and this
condition was further aggravated by continued adherence
to the exercise regime. Hindlimb muscles (gastrocnemius
and TA) of one-month exercised mice displayed a higher
degree of fibrosis, identified by Sirius red staining, withrespect to normally active non-exercised mdx control
mice (Figure 3A, and Figure S2A in Additional file 3). The
increased fibrosis observed by Sirius red staining was con-
firmed by Coll I immunofluorescence (Figure 3B, upper
panels, and Figure S2B in Additional file 3), and the greater
deposition of FN (Figure 3B, and Figure S2B in Additional
file 3, lower panels) that is normally only observed in old
mdx limb muscles (Figure 2G). Consistent with this, colla-
gen content and the expression of TGFβ1 and CTGF
mRNA, and the levels of P-Smad2/3 proteins, were in-
creased in exercised dystrophic mdx muscles, compared to
non-exercised controls (Figure 3C, D, E, and Figure S2C in
TA











































































































































































Figure 2 Quantification of fibrosis in muscle of mdx mice. (A) Sirius red and H&E staining of mdx tibialis anterior (TA) (upper panels) and
diaphragm (lower panels) muscles at different ages compared to adult wild-type (WT) muscle. ‘Young’ corresponds to muscles of three-month-old mice,
‘Adult’ to nine months and ‘Old’ to eighteen to twenty-four months of age. (B) and (C) Active transforming growth factor beta 1 (TGFβ1) protein quantifi-
cation by ELISA in TA and diaphragm muscles of WT and mdx mice at the indicated ages, respectively. Data correspond to the mean ± SEM values; n = 4
for each group. Two-way analysis of variance with Tukey’s post hoc multiple comparison test. **P <0.01, ***P <0.001 versus age-matched WT. (D) and (E)
Quantification of collagen content in TA and diaphragm muscles of WT and mdx mice at different ages. Values are mean ± SEM; n = 4 for each group.
Two-way analysis of variance with Tukey’s post hoc multiple comparison test. **P <0.01, ***P <0.001 versus control WT values. (F) Relative expression of
collagen I, connective tissue growth factor (CTGF), tissue inhibitor of metalloproteinases 1(TIMP-1) and TGFβ1 mRNA by quantitative RT-PCR in mdx TA
muscles at the indicated ages with respect to WT muscles (baseline set arbitrarily to 1). Values are mean ± SEM; n = 3 for each group. Two-way analysis of
variance with Tukey’s post hoc multiple comparison test. *P <0.05, **P <0.01, ***P <0.001, versus age-matched WT. (G) Representative pictures of immuno-
fluorescence staining for collagen I (green) and fibronectin (red) in young, adult and old mdx TA, compared to WT muscle. Scale bars = 50 μm.
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Figure 3 (See legend on next page.)
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Figure 3 Effect of exercise on muscle fibrosis in mdx mice. (A) Sirius Red and H&E staining of gastrocnemius muscle of mdx mice that were
exercised three times weekly, for 30 minutes at a speed of 12 meters per minute with a rest of 5 minutes each 10 minutes of exercise, for one,
two and three months, compared to sections of muscle from unexercised mdx mice. All the samples were collected when the animals were six
months old (see the Methods section). (B) Representative immunofluorescence for collagen I and fibronectin in muscle sections of control or
exercised mice as shown in (A). (C) Quantitative RT-PCR of connective tissue growth factor (CTGF) and transforming growth factor beta 1 (TGFβ1)
mRNA levels after exercising for the indicated period as compared to unexercised age-matched mdx mice. Data correspond to the mean ± SEM;
n = 4 sedentary and 4 exercised mdx mice for each exercise time point. One-way analysis of variance with Tukey’s post hoc multiple comparison
test; *P <0.05, **P <0.01, ***P <0.001 versus control. (D) Biochemical quantification of collagen protein content in mdx gastrocnemius muscle after
exercising for the indicated periods, as compared to unexercised age-matched mdx mice. Data correspond to the mean ± SEM; n = 4 sedentary
and 4 exercised mdx mice for each exercise time point. One-way analysis of variance with Tukey’s post hoc multiple comparison test; *P <0.05,
**P <0.01, ***P <0.001 versus control. (E) Immunofluorescence for phosphorylated-Smad2/3 proteins on sections from gastrocnemius muscle of
six-month-old mdx mice after three months of exercise, as evidence for TGFβ activation, compared to unexercised age-matched control mdx
mice. (F) Ex vivo maximum isometric force (tetanic force) of gastrocnemius muscle of age-matched unexercised and three-month-trained mdx
mice. Values as mean ± SEM; n = 7 on each group. Non-parametric Mann–Whitney U test; **P <0.01 versus non-exercised. Scale bars = 50 μm.
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muscles of mdx mice subjected to the exercise regime was
decreased with respect to non-exercised mice (Figure 3F,
and Figure S2D in Additional file 3). These data confirm
that exercise in young mdx mice can activate fibrogenesis,
and in particular the profibrotic TGFβ pathway, and
thereby enhance and anticipate muscle tissue fibrosis.
Surgical muscle injuries advance and enhance fibrosis in
young dystrophic mice
We next sought alternative and faster ways than long-
term exercise training to induce fibrosis in limb muscles
of young mdx mice, based on inflicting increased surgical
or chemical damage. Since CTX-induced muscle injury is a
widely used and well-characterized experimental model for
inducing skeletal muscle degeneration/regeneration [26-28],
we hypothesized that superimposing CTX-induced damage
on young dystrophic mdx muscle would promote fibrosis.
Despite an early increase in collagen content, two weeks
after intramuscular CTX injection (50 μl of 10–5 M), TA
mdx muscle showed a similar quantity of deposited colla-
gen compared to non-injured (NI) mdx TA indicating that
the fibrogenic effect of CTX-induced damage was transient
(Figure 4A). To increase and prolong collagen deposition,
we superimposed on young mdx limb muscle two more
extreme, but distinct, experimental paradigms: lacer-
ation (LAC) and denervation (DEN). The DEN model
involves severing the sciatic nerve thus causing atrophy
of the denervated myofibers [14,29], while the LAC
model consists in a deep cut across the muscle, which
causes a delay in the healing process [11,12]. Muscle of
dystrophic mdx mice at two weeks after DEN showed
an increased deposition of collagen relative to CTX-
injured mdx muscle (Figure 4A, C). Lacerated dystrophic
muscle also showed increased fibrosis after two weeks,
which was even higher than in denervated muscle after
the same time period (Figure 4A, C). Importantly, the
mdx muscle fibrosis induced by both methods persisted
for up to two months, as indicated by histological andbiochemical parameters (see below, Figure 4F and G). This
extended fibrotic status reinforces the utility of these two
methods as drivers of limb muscle fibrosis in young mdx
mice, after which the tissue more closely resembles the
more severe phenotype of old mdx mice, as well as human
DMD patients. Furthermore, these procedures have the
advantage of not requiring exercise devices, nor the time
and labor of the three-month exercise protocol.Raising TGFβ levels in dystrophic muscle of young mdx
mice accelerates fibrosis and accentuates disease severity
Despite the profibrotic effect of the surgical methods on
mdx muscle, each one has particularities and limitations.
In the LAC model, the injury is confined to a small area
of the muscle and this reduces the amount of tissue
available for further studies, whereas, for reasons of ani-
mal welfare, DEN can only be performed in one leg of
the mouse, affecting only the muscles under the knee.
Therefore, based on our observation of the elevated levels
of TGFβ in human and mouse dystrophic muscle (Figures 1
and 2), and its correlation with the extent of dystrophy-
associated fibrosis, we reasoned that exogenous delivery of
TGFβ1 to muscle of young dystrophic mice might increase
and accelerate the development of fibrosis. We therefore
performed two intramuscular TA injections of TGFβ1
(50 ng of TGFβ1 in 50 μl of PBS per injection), spaced
seven days apart, in an attempt to sustain the profibrogenic
action of this growth factor. Contralateral control muscles
received the same number of injections of PBS. Analysis of
the muscles histologically by H&E and Sirius red staining
showed that TGFβ1 delivery lead to substantial increase in
collagen deposition already at two weeks after the first in-
jection, which persisted for up to two months and this was
also confirmed by biochemical quantification of muscle
extracts (Figure 4B and C). Of note, local muscle overex-
pression of the TGFβ1 target gene product CTGF also in-
creased fibrogenesis in limb muscle of young mdx mice
(Figure S3A, B in Additional file 4).
A B TGFβ   N.I.               CTX                       DEN                     LAC


































































































































   
   









   
   









Figure 4 (See legend on next page.)
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Figure 4 Induction of fibrosis after chemical and surgical muscle damage in young mdx mice. (A) Sirius red and hematoxylin and eosin
(H&E) staining of tibialis anterior (TA) muscles of young (three-month-old) mdx mice two weeks after cardiotoxin (CTX)-injury (50 μl of 10–5 M),
denervation (DEN) and laceration (LAC), compared to non-injured (NI) muscle of sham-operated mdx mice. (B) Sirius red and H&E staining of
young mdx TA muscle analyzed after two sequential treatments with recombinant transforming growth factor beta 1 (TGFβ1) (50 ng in 50 μl
phosphate-buffered saline (PBS)) spaced seven days apart. (C) Biochemical quantification of collagen protein content in mdx TA, two weeks after
different treatments relative to uninjured mdx control. Values represent mean ± SEM; n = 4 on each group. Non-parametric Mann–Whitney U test;
*P <0.05 versus NI. (D) Quantitative RT-PCR of collagen I, connective tissue growth factor (CTGF), tissue inhibitor of metalloproteinases 1(TIMP-1)
and TGFβ1 mRNA expression in mdx muscle two weeks after different injuries versus control mdx mice. Values represent mean ± SEM; n = 4 on
each group. Non-parametric Mann–Whitney U test; *P <0.05 versus NI. (E) Representative immunostaining for collagen I (green) and fibronectin
(red) on sections of young mdx TA muscles two weeks after injury relative to control. (F) Sirius Red and H&E staining of mdx TA muscle two
months after CTX injury, DEN, LAC or injection of TGFβ in three-month-old mdx muscle compared to NI mdx control muscle. (G) Quantification
of collagen content in TA muscle of young mdx mice two months after different treatments, as described above. Values represent mean ± SEM;
n = 4 on each group. Non-parametric Mann–Whitney U test; *P <0.05 versus NI. (H) Ex vivo maximum isometric force (tetanic force) of TA muscle
of young mdx mice two months after treatments. Values as mean ± SEM; n = 4 to 5 on each group. Non-parametric Mann–Whitney U test;
*P <0.05; **P <0.01 versus NI. Scale bars = 50 μm.
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tional parameters in all the procedures tested revealed
that LAC and TGFβ treatments gave statistically higher
quantitative measures of collagen than NI age-matched
control mdx muscles. The collagen values for LAC and
TGFβ1 treatments were comparable to the values re-
corded in limb muscles of old mdx mice (see Figure 2D),
indicating that either one of these methods advances fibro-
sis by the equivalent of about fourteen months (that is in-
ducing fibrosis at four months of age instead of eighteen
months). DEN also significantly increases muscle collagen
content over mdx controls, but to a lesser extent than LAC
or TGFβ1 treatment (Figure 4A and C). Interestingly, the
levels of endogenous TGFβ1 mRNA were increased in
young dystrophic muscle in response to LAC, DEN and ex-
ogenous TGFβ1 delivery, but not CTX. Consistent with
this, the expression of TGFβ-dependent signaling fibrotic
target genes, such as, Coll I, CTGF, TIMP-1, were increased
in mdx limb muscle after all three treatments, but not in
CTX-damaged muscle (Figure 4D). Finally, immunostain-
ing for FN and Coll I on sections from the different dam-
aged mdx muscles showed greater ECM production than
uninjured (or CTX-injured) dystrophic muscle (Figure 4E).
Remarkably, at two months after injury, collagen depos-
ition still persisted in TGFβ-treated young dystrophic mus-
cles as it did in lacerated and denervated muscles, as
revealed by histological and biochemical analysis (Figure 4F
and G). In agreement with this, and demonstrating the
deleterious physiological consequences of the increased fi-
brosis in young mdx muscles, the maximum force of the
muscles subjected to the distinct treatments decreased with
respect to NI mdx muscles (Figure 4H), therefore better
mimicking the severe phenotype of the human condition.
Induction of fibrosis in non-dystrophic, wild-type muscle
by combining surgical injury and growth factor delivery
Fibrosis persistence has negative consequences on tissue
wound healing. Severe muscle injuries caused by trauma
often result in scar formation at the expense of tissuerepair. Thus, we designed easy-to-perform profibrotic
procedures in non-dystrophic WT muscle, which could
ideally be extended to a wide variety of transgenic mouse
lines for research or therapeutic purposes.
We applied the surgical/chemical methods previously
used on muscle of dystrophic mdx mice (see above), ei-
ther alone or in combination, to induce muscle fibrosis
in WT mice. First, we performed CTX injury in TA
muscle of WT mice and assessed fibrosis development.
We observed a mild and transient deposition of ECM
between days 5 and 7 after CTX (50 μl of 10–5 M)
muscle injury (Figure S4A and B in Additional file 5);
however, it did not persist beyond this stage. Indeed, two
weeks after CTX injury, collagen content returned to
near basal levels, in agreement with efficient muscle re-
covery (Figure 5A-C and Figure 6H).
We next subjected WT muscle to the more severe
LAC and DEN procedures and compared the fibrosis
index of the affected muscles to that of CTX-injured
muscle at similar time points. LAC in TA muscle of WT
mice disrupted the tissue quite extensively and for a pro-
longed period of time (over one month) resulting in sus-
tained fibrosis, which correlated with the slow kinetics
for regeneration (Figure 5A, B). DEN, in turn, did not
alter ECM production significantly, as revealed by H&E
and Sirius red staining, or immunostaining for Coll I
and FN, despite inducing the expected myofiber atrophy.
Consistent with these findings, we only observed statisti-
cally significant increases in the expression of TGFβ1
and the fibrotic markers Coll I, FN, CTGF and TIMP-1 in
lacerated muscle, but not in denervated or CTX-injured
muscles, compared to uninjured muscle (Figure 5C).
These results suggest that LAC is the most fibrotic of the
traumatic models tested in non-dystrophic mice.
As stated above, one of the limitations of the LAC pro-
cedure is the restricted availability of biopsy material. Try-
ing to induce fibrosis by methods that would render more
fibrotic tissue available for analysis, we decided to combine
CTX injury, which individually was a poor fibrosis-inducing
























































   
   







   
   




   
   
   
   










Figure 5 Quantification of muscle fibrosis after chemical and surgical damage in wild-type mice. (A) Sirius red, hematoxylin and eosin
(H&E), collagen I (green) and fibronectin (red) staining on wild-type (WT) tibialis anterior (TA) muscles two weeks after cardiotoxin (CTX) injury
(50 μl of 10–5 M), laceration (LAC) and denervation (DEN) compared to non-injured (NI) muscle of sham-operated WT mice. (B) Quantification of
collagen content in WT muscle after different injuries. Data correspond to the mean ± SEM; n = 4 on each group. Non-parametric Mann–Whitney
U test; *P <0.05 versus NI. (C) Quantitative RT-PCR for collagen I, connective tissue growth factor (CTGF), tissue inhibitor of metalloproteinases 1
(TIMP-1) and transforming growth factor beta 1 (TGFβ1) mRNA in muscles after the different injuries (values are means ± SEM; n = 4 on each
group. Non-parametric Mann–Whitney U test; *P <0.05 versus NI). Scale bar = 50 μm.
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muscle of WT mice, methods which we previously showed
were able to increase fibrosis in young mdx muscle
(Figure 4). Both DEN and injection of TGFβ1 failed to
induce fibrosis in WT muscles when used alone (Figure 5,
and Figure S4C and D in Additional file 5). Accordingly,TA muscles of WT mice were first subjected to CTX injec-
tion (50 μl of 10–5 M) and subsequently denervated or
injected twice with TGFβ1 (50 ng of TGFβ1 in 50 μl PBS
per injection) (at day 7 and 10 after CTX injection) and
muscles were collected two and four weeks later. We found
that the combination of CTX injury with DEN or TGFβ1
CTX                   CTX+DEN             CTX+TGFβ A B
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Figure 6 Synergistic effect on fibrosis induction in muscle of wild-type mice by combined treatments. (A) Sirius red and hematoxylin and
eosin (H&E) staining of wild-type (WT) tibialis anterior (TA) muscles subjected to a combination of cardiotoxin (CTX) injury (50 μl of 10–5 M) and denerv-
ation or transforming growth factor beta 1 (TGFβ1) (50 ng in 50 μl phosphate-buffered saline (PBS)) injection (as described in the Methods section),
respectively, compared to CTX injury alone. (B) Quantification of collagen content in muscle after each treatment. Data correspond to the mean ±
SEM; n = 4 on each group. Non-parametric Mann–Whitney U test; *P <0.05 versus CTX injury. (C) Quantitative RT-PCR for collagen I, connective tissue
growth factor (CTGF), tissue inhibitor of metalloproteinases 1 (TIMP-1) and TGFβ1 after the different treatments (n = 4 on each group. Non-parametric
Mann–Whitney U test; *P <0.05, compared to CTX injury). (D) Representative immunostaining for collagen I (green) and fibronectin (red) on sections of WT
muscle subjected to the different fibrosis-inducing methods. (E-G) Analysis of long-term fibrosis in WT muscle at one month after injury. Data are compared
to non-injured (NI) muscle of sham-operated WT mice. (E) Sirius red and H&E staining of CTX-injured, lacerated, CTX/denervation and CTX/TGFβ-injured
muscles at one month after injury. (F) Quantification of collagen content one month after injury of WT muscle. Values represent mean ± SEM; n = 4 on each
group. Non-parametric Mann–Whitney U test; *P <0.05 versus NI. (G) Ex vivo maximum isometric force (tetanic force) of TA muscle. Values as mean ± SEM;
n = 4 on each group. Non-parametric Mann–Whitney U test; *P <0.05 versus NI. Scale bars = 50 μm.
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jury alone, as shown by Sirius red staining (Figure 6A), col-
lagen quantification as well as expression of fibrotic
markers by quantitative RT-PCR and immunohistochemis-
try analyses, after 14 days (Figure 6B-D), correlating with
delayed regeneration kinetics (Figure 6A). Of note, a com-
bination of CTX injury and CTGF local overexpression
produced similar profibrotic effects as combining CTX in-
jury and TGFβ1 delivery (Figure S3C in Additional file 4),
suggesting that part of the TGFβ profibrotic actions are
likely to be mediated by CTGF.
We next compared the persistence of fibrosis over
time and the consequences on muscle function of each
of the distinct fibrogenic regimes on WT muscle. Sirius
red staining and collagen quantification showed that
muscle fibrosis still persisted after four weeks of either
laceration or CTX combined with TGFβ1 or DEN, com-
pared to muscle injured with CTX alone or NI muscle
(Figure 6E and 6F). The relevance of these results was
supported by functional studies of WT muscle after the
combined profibrotic treatments (CTX combined with
TGFβ1 or DEN). Indeed, dual treatments on muscles
exerted a synergistic effect, resulting in increased fibrosis
and reduced net force compared to uninjured muscle or
muscle injured with CTX alone (Figure 6G). These re-
sults suggest that in WT mice, LAC, as well as a com-
bination of CTX injury with either DEN or TGFβ1,
proved to be effective fibrosis-inducing models that trig-
ger a rapid accumulation of fibrotic tissue that is sus-
tained for an extended period of time, with negative
consequences on muscle function.
Finally, and in order to further expand the variety of
fibrogenic-inducing procedures to the maximum number
of laboratories working on skeletal muscle, we tested the
fibrosis-inducing effect of a widely used muscle-damaging
method involving BaCl2 injection in WT muscle. We
found that, as for CTX injection, one intramuscular injec-
tion of BaCl2 (50 μl of 0.2% BaCl2) only induced a very mild
and transient accumulation of ECM. Of note, repeated in-
jections (spaced one week) for up to six weeks resulted in
significant ECM accumulation after eight weeks from the
first injection (that is two weeks after the last injection),
although no major change in muscle force was observed
(Figure 7A-C). Thus, repeated damaging with myotoxins
may be a fibrosis-inducing alternative in non-dystrophic
muscle, although development of fibrosis requires up to
eight weeks, and involves weekly mouse manipulation for
six weeks, compared to the less labor-consuming and
more rapid fibrogenic effect (with additional impact on
muscle force) of the combined treatments.
Discussion
Muscular dystrophies constitute a heterogeneous group
of inherited myopathies, characterized by progressivemuscular degeneration, of which DMD is one of the se-
verest. Progressive replacement of skeletal muscle by fat
and fibrotic tissue not only exacerbates disease progres-
sion, but also impairs the efficiency of gene- and stem cell-
based therapies [30,31]. Yet, there is no effective clinical
treatment to reverse or attenuate fibrosis in DMD patients,
except for promising new agents such as halofuginone
[32]. To a great extent, this deficit may derive from the
poor understanding of the mechanisms underlying fibro-
genesis in muscular dystrophy. Indeed, chronic inflamma-
tion and production of collagens by myoblasts are among
the few reported causal factors promoting progression to
fibrosis in dystrophic muscle [33-38]. The largely unknown
etiology of fibrogenesis in DMD in turn may be principally
due to the lack of adequate animal models of muscle fibro-
sis. Here we report the application of simple models of
tissue damage that are able to significantly enhance the
fibrotic response in skeletal muscle and which may be
useful for investigating therapeutic strategies for DMD.
Studies using mdx mice, the most common mouse
model of DMD, may not be translated directly to dys-
trophic patients due to the mild phenotype they display.
In particular, limb muscles of mdx mice show a relatively
efficient regeneration and no significantly aberrant de-
position of ECM proteins until very old age. Progressive
endomysial fibrosis only develops in diaphragm muscle,
but is still not significantly advanced until well into
adulthood [39]. To try to accelerate or exacerbate this
phenotype, other mouse models have been generated such
as mdx mice lacking arginase-2, PAI-1 (plasminogen acti-
vator inhibitor-1) or Cmah (cytidine monophosphate-
sialic acid hydroxylase) [11,40,41] and previously the mdx/
utrn+/− mouse line (mdx mice with haploinsufficiency of
utrophin) [42]. However, mdx/utrn+/− mice show early
mortality and the manipulation of the line requires time
and resources in genotyping and breeding. Moreover, the
genetics of these mouse models do not adequately reflect
human DMD patients. Therefore, the need for fibrotic
models that do not require waiting for the natural physio-
logical onset of fibrosis in the hindlimb of old mice, and
that recapitulate the human DMD phenotype becomes in-
creasingly more important. One recent attempt to address
this problem came from Desguerre and colleagues (2012)
who described a model of mechanical muscle injury by
daily repeated micro-punctures in mdx hindlimb muscle
[43]. Induction of endomysial fibrosis in dystrophic muscle
through this method is ascribed to a small fibrotic area
and requires daily animal manipulation during two weeks.
In addition, this procedure does not seem to induce fibro-
sis in WT mice [43].
The strategies we propose here are valid alternatives to
both hasten the appearance and prolong the duration of
fibrosis in hindlimb muscles of young mdx mice, with
very limited (non-daily) animal manipulation, which









   
   
   
   
   




   
   
   
   
   
   





















































Figure 7 Fibrosis induction in muscle of wild-type mice after repeated BaCl2 injuries. (A) Sirius red, H&E and fibronectin staining on wild-type
(WT) tibialis anterior (TA) muscles subjected to one or six consecutive weekly rounds of BaCl2 injections (50 μl of 0.2% BaCl2), compared to non-injured
(NI) muscle of sham-operated WT mice, sampled two weeks after the final injection. (B) Quantitative expression of fibronectin and collagen I in the
distinct muscle samples (values are means ± SEM; n = 4 to 5 on each group. Non-parametric Mann–Whitney U test; **P <0.05 versus NI). (C) Ex vivo
maximum isometric force (tetanic force) of TA muscle. Values as mean ± SEM; n = 4 for each group; non-parametric Mann–Whitney U test; no
significant differences P >0.05. Scale bar = 50 μm.
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sis in WT muscle. Therefore, these methods would be
applicable to other genetically modified mice, and this
will help further delineating the cellular and genetic
basis of muscle fibrosis. Exercise training of young mdx
mice induced endomysial fibrosis, resembling the pheno-
type of old hindlimb dystrophic muscles; however,
although this method can be considered more physio-
logical, it still requires a lengthy time period to obtain a
fibrotic muscle tissue, in addition to significant amount of
effort and time, since exercise protocols need to be applied
several times a week for ideally three months. At variance,
the methods based on muscle growth factor delivery and
surgical injuries that we present here offer a faster and less
labor-intensive alternative. The rationale for the proposed
profibrotic growth factor-based methods relies on the ob-
servation that, in fibrotic muscles of human DMD patients
and old mdx mice, TGFβ1 (and its downstream target
CTGF) is present at high levels [22,44], correlating with
the increased activation of Smad2/3 transcriptional me-
diators (see Figure S5 in Additional file 6). Of the surgi-
cal methods tested, muscle laceration proved to be the
most effective for inducing sustained fibrosis; however,
this method has the disadvantage that the affected area
is relatively small (and only one muscle per mouse can
be lesioned due to the severity of the procedure) thereby
limiting the amount of material available for downstream
processing. Subsequent cellular analysis of fibrotic muscle
by techniques such as fluorescence-activated cell sorting
(FACS) may not be possible in this type of model without
vast improvements of sensitivity or without increasing the
number of animals used, which has extra cost and ethical
implications. Sciatic nerve denervation of mdx mice gen-
erates increased collagen deposition, as a possible mech-
anism to replace the tissue volume lost due to myofiber
atrophy. All of these fibrogenesis-inducing methods per-
sist with time, since at two months after injury muscles
still displays a fibrotic phenotype. Moreover, consistent
with the idea that fibrosis aggravates muscle dysfunction
in DMD, we showed that maximal muscle force was also
reduced in young mdx mice after fibrosis induction
through the different protocols.
Finally, to be able to investigate fibrosis development
and therapeutic options in muscle of non-dystrophic
models, we sought to apply these methods to WT mice.
To date, studies on muscle damage in non-dystrophic
models have been performed classically with a single in-
jection of myotoxins (for example, CTX or BaCl2). Des-
pite the general use, we have shown in this study that
these standard single-injury methods are not appropriate
fibrosis-inducing models, as the resolution of the dam-
age occurs rapidly and collagen deposition is very mild
and only transient. On the contrary, muscle laceration of
WT muscle induces a massive collagen deposition thatis relatively stable over long periods of time, despite af-
fecting only a localized small tissue area. However, the
combination of regimes showed an improved capacity to
generate fibrosis in WT muscle for a sustained period of
time, correlating with reduction in muscle force, indicat-
ing that they mimic in WT animals pathophysiological
situations of severe muscle trauma that result in aber-
rant regeneration, scar deposition and functional impair-
ment. We propose that this variety of fibrosis-inducing
methodologies will enable fibrosis to be studied in a vast
array of transgenic mouse lines (with no apparent under-
lying muscle pathology) or after crossing them with dys-
trophic strains such as mdx mice.
Conclusions
Collectively, through this study, we propose novel and/or
optimized experimental strategies to accelerate, anticipate
and boost muscle fibrosis in young dystrophic mice or to
drive de novo fibrosis onset in WT mice. We think that
our findings provide very useful methodologies that will fa-
cilitate research in the emerging field of skeletal muscle fi-
brosis. In particular, these rapid and feasible procedures for
most laboratories will help getting deeper insight into the
mechanisms underlying muscle fibrosis, as well as develop-
ing therapeutic strategies aimed to reduce its magnitude in
dystrophic diseases and to ameliorate dystrophy progres-
sion. Since fibrosis is also a main obstacle for stem cell en-
graftment, availability of appropriate fibrosis models will be
a determinant factor in the research toward successful
gene/cell therapy-based strategies in muscular dystrophy.
Additional files
Additional file 1: Table S1. Methods and sampling times of the
different fibrosis-inducing procedures in mdx and wild-type (WT) mice.
Additional file 2: Figure S1. Quantification of fibrosis in mdx
diaphragm muscle. (A) Relative expression of collagen I, connective tissue
growth factor (CTGF), tissue inhibitor of metalloproteinases 1(TIMP-1) and
transforming growth factor beta 1 (TGFβ1) mRNA by quantitative RT-PCR
in mdx diaphragm muscles at the indicated ages respect to wild-type
(WT) muscles. Values are mean ± SEM; n = 4 for each group; non-
parametric Mann–Whitney U test; *P <0.05 versus age-matched WT. (B)
Representative pictures of immunofluorescence staining for collagen I
(green) and fibronectin (red) in young, adult and old mdx diaphragm,
compared to age-matched WT muscle. Scale bars = 50 μm.
Additional file 3: Figure S2. Effect of exercise on tibialis anterior (TA)
mdx muscle. (A) Sirius red and hematoxylin and eosin (H&E) staining of
TA muscle of mdx mice that were exercised three times weekly, for
30 minutes at a speed of 12 meters per minute with a rest of 5 minutes
each 10 minutes of exercise, for one, two and three months, compared
to sections of muscle from unexercised mdx mice. All the samples were
collected when the animals were six months old (see the Methods
section). (B) Representative immunofluorescence for collagen I and
fibronectin in muscle sections of control and exercised mice as shown in
(A). (C) Biochemical quantification of collagen protein content in mdx TA
muscle after exercising for the indicated period as compared to unexercised
age-matched mdx mice. Data correspond to the mean ± SEM; n = 4 sedentary
and 4 exercised mdx mice for each exercise time point. One-way analysis of
variance with Tukey’s post hoc multiple comparison test; **P <0.01, ***P <0.001
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http://www.skeletalmusclejournal.com/content/4/1/7versus control. (D) Ex vivo maximum isometric force (tetanic force) of TA
muscle of age-matched unexercised and three-month-trained mdx mice.
Values as mean ± SEM; n = 7 on each group. Non-parametric Mann–Whitney
U test; **P <0.01 versus non-exercised. Scale bars = 50 μm.
Additional file 4: Figure S3. Fibrosis induction in muscle by viral
delivery of connective tissue growth factor (CTGF). (A) Mdx mice: Sirius
red and hematoxylin and eosin (H&E) staining of mdx tibialis anterior (TA)
muscles overexpressing mouse CTGF after intramuscular injection of
50 μl of 2x1011 particles of adenovirus (AdV) in three-month-old mice.
(B) Collagen content quantification. Data correspond to the mean ± SEM;
n = 4 on each group. Non-parametric Mann–Whitney U test; *P <0.05
versus NI. (C) Wild-type (WT) mice: H&E of WT muscles after adenoviral
CTGF delivery coupled with cardiotoxin (CTX) injury; representative
immunostaining for collagen I (green) and fibronectin (red) on sections
of AdV-transduced muscle overexpressing CTGF. Scale bars = 50 μm.
Additional file 5: Figure S4. Collagen deposition after cardiotoxin
(CTX)-induced muscle injury and transforming growth factor beta 1
(TGFβ1) delivery alone is quickly resolved in wild-type (WT) mice. (A)
Sirius red, hematoxylin and eosin (H&E), collagen I (green) and fibronectin
(red) staining on WT tibialis anterior (TA) muscles after five and eight days
from CTX injury, compared to non-injured (NI) muscle of sham-operated
WT mice. (B) Quantification of collagen content in muscle after treatment.
Data correspond to the mean ± SEM, n = 4 on each group. Non-parametric
Mann–Whitney U test; *P <0.05 versus NI. (C) Sirius red, H&E, collagen I (green)
and fibronectin (red) staining on WT TA muscle two weeks after two sequen-
tial treatments with recombinant TGFβ1 (50 ng in 50 μl phosphate-buffered
saline (PBS)), spaced seven days apart. (D) Quantification of collagen content
in muscle after injection of TGFβ1 or PBS (vehicle). Data are mean ± SEM, n = 4
for each group. Non-parametric Mann–Whitney U test; no significant differ-
ences P >0.05. Scale bars = 50 μm.
Additional file 6: Figure S5. Smad2/3 protein phosphorylation in
injured muscles. Immunofluorescence for phosphorylated-Smad2/3 proteins
on sections from tibialis anterior (TA) muscle of mdx (A) and wild-type (WT)
(B) mice after the indicated treatments. Scale bars = 50 μm.
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factor; CTX: cardiotoxin; DEN: denervation; DMD: Duchenne muscular
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